SunBio,Inc.
Financials
Valuation Metrics
SunBio,Inc.'s Market Cap is ₩633B. At end of 2025 it was ₩694B. Ranked #1552 of 2,405 in KR market (top 65%), #906 of 1,627 on KOSDAQ (top 56%), #171 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 63.27B KRW | KR#1,552/2,405 Sec#171/231 |
| Revenue | 12.45B KRW | KR#2,246/2,405 Sec#171/231 |
| Net Income | 4.31B KRW | KR#1,259/2,405 Sec#87/231 |
| Total Assets | 64.17B KRW | KR#2,061/2,405 Sec#177/231 |
| Net Assets | 29.96B KRW | KR#2,168/2,405 Sec#195/231 |
| Employees | 23 | KR#2,224/2,405 Sec#210/231 |
| Value | ||
| P/E | 14.67x | KR#1,082/2,405 Sec#66/231 |
| P/B | 2.11x | KR#2,008/2,405 Sec#153/231 |
| PEG | 0.02x | KR#191/2,405 Sec#8/231 |
| P/S | 5.08x | KR#2,161/2,405 Sec#147/231 |
| EV/EBITDA | 20.13x | KR#1,053/2,405 Sec#63/231 |
| FCF Yield | 0.91% | KR#1,149/2,405 Sec#86/231 |
| Profitability | ||
| ROE | 14.40% | KR#349/2,405 Sec#24/231 |
| ROA | 6.72% | KR#547/2,405 Sec#43/231 |
| Op. Margin | 35.90% | KR#34/2,405 Sec#7/231 |
| Revenue Growth | 25.12% | KR#449/2,405 Sec#44/231 |
| Earnings Growth | 732.15% | KR#81/2,405 Sec#6/231 |
| Financial Health | ||
| Debt Ratio | 114.16% | KR#1,656/2,405 Sec#190/231 |
| Total Debt | 30.62B KRW | KR#1,216/2,405 Sec#91/231 |
| FCF | 576.6M KRW | KR#1,170/2,405 Sec#89/231 |
| Cash | 3.87B KRW | KR#2,093/2,405 Sec#198/231 |
| Current Ratio | 0.46x | KR#2,146/2,405 Sec#210/231 |
| Net Debt/EBITDA | 5.98x | KR#1,080/2,405 Sec#81/231 |
| Performance | ||
| 1Y Return | -4.95% | KR#615/2,405 Sec#34/231 |
| 1M Return | -4.07% | KR#618/2,405 Sec#63/231 |
| From 52W High | -39.06% | KR#717/2,405 Sec#49/231 |
| 1Y MDD | -37.52% | KR#474/2,405 Sec#32/231 |
| Trading | ||
| Volume | 3,732 shares | KR#2,171/2,405 Sec#220/231 |
| Trading Value | 19.3M KRW | KR#2,102/2,405 Sec#215/231 |
| Foreign Own. | 0.32% | KR#2,239/2,405 Sec#216/231 |
| Per Share | ||
| EPS | 353 KRW | KR#1,103/2,405 Sec#77/231 |
| BPS | 2,453 KRW | KR#1,975/2,405 Sec#158/231 |
Company Info
Seonbio, established in 1997 and listed on KOSDAQ in 2022 as a technology growth company, specializes in the research, development, production, and sales of biopharmaceuticals, medical devices, and PEG derivatives. Utilizing its PEGylation technology, the company has commercialized various biopharmaceuticals, biosimilar drugs, and medical devices. Its neutropenia treatment Pegfilgrastim biosimilar is sold in the EU, Canada, Australia, and India, while the dry mouth treatment MucoPEG received US FDA sales approval in 2019.